查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2132387

傷口護理生物製劑市場規模、佔有率和趨勢分析報告：按產品、應用、最終用途、地區和細分市場分類（2026-2033 年）

Wound Biologics Market Size, Share & Trends Analysis Report By Product, By Application, By End-use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

傷口生物製劑市場概述

全球傷口生物製劑市場預計到 2025 年將擴大到 26 億美元，到 2026 年將成長到 28 億美元，到 2033 年將擴大到 48 億美元，2026 年至 2033 年的年複合成長率（CAGR）為 8.1%。

北美市場主導地位，預計到 2025 年將佔全球銷售額的 43.5%。傷口生物製劑產業的成長主要受慢性傷口（如糖尿病足潰瘍、靜脈潰瘍和壓瘡）盛行率上升以及全球糖尿病負擔加重和人口老化等因素的推動。

對先進再生醫學的需求不斷成長，生物工程皮膚替代品和生長因子產品的持續創新，以及生物衍生創傷護理解決方案在促進癒合和減少併發症的臨床應用日益增多，這些因素進一步推動了市場成長。

慢性傷口和糖尿病盛行率的不斷上升是傷口生物製劑市場的主要成長要素。這是因為糖尿病足潰瘍、靜脈性腿部潰瘍、壓瘡和其他難癒合傷口需要先進的療法來促進組織再生和加速癒合。根據國際糖尿病聯盟 (IDF) 統計，全球糖尿病患者人數持續成長，慢性傷口併發症的高風險族群數量也在增加。包括皮膚替代物、胎盤組織同種異體移植和細胞外基質 (ECM) 療法在內的生物創傷護理產品正被應用於複雜傷口患者的治療，以改善癒合效果、降低感染風險並減少截肢率。

外科手術和創傷病例的不斷增加是傷口生物製劑市場的主要驅動力。這些病例通常需要先進的傷口管理，以促進組織再生並降低感染和延遲癒合等併發症的風險。傷口生物製劑，例如皮膚替代物、羊膜同種異體移植片和基於細胞外基質（ECM）的療法，擴大應用於複雜的外科性創傷、整形外科手術、燒傷和創傷病例。全球外科手術數量的增加以及交通事故、運動傷害和燒傷發生率的上升，持續擴大醫院和創傷中心對再生性傷口生物製劑的需求。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 傷口護理生物製劑市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 傷口護理生物製劑市場分析工具

第4章 傷口護理生物製劑市場：產品具體估算與趨勢分析

  • 全球傷口護理生物製劑市場：基於產品的趨勢分析，2025 年和 2033 年
  • 全球傷口護理生物製劑市場：基於產品的規模和趨勢分析，2021-2033年
  • 生物基皮膚替代品
    • 同種異體移植
    • 異質骨移植
    • 生物合成產物
  • 外用製劑
  • 膠原蛋白敷料

第5章 傷口生物製劑市場：依傷口類型分類的估算與趨勢分析

  • 全球傷口護理生物製劑市場：按傷口類型分類的趨勢分析（2025 年和 2033 年）
  • 全球傷口生物製劑市場：以傷口類型分類的規模和趨勢分析（2021-2033年）
  • 慢性傷口
  • 急性傷口

第6章 傷口生物製劑市場：依最終用途分類的估算與趨勢分析

  • 全球傷口護理生物製劑市場：按最終用途分類的趨勢分析（2025 年和 2033 年）
  • 全球傷口護理生物製劑市場：按最終用途分類的規模和趨勢分析（2021-2033年）
  • 醫院
  • 專科診所
  • 門診手術中心
  • 其他

第7章 傷口護理生物製劑市場：區域估算與趨勢分析

  • 區域儀錶板
  • 市場規模及趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 丹麥
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 主要市場參與企業的最新趨勢及影響分析
  • 公司分類
  • 企業市場占有率分析，2025 年
  • 企業熱力圖分析
  • 策略規劃
    • 業務拓展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 研究與開發
    • 公司簡介
    • MIMEDX Group, Inc
    • Integra生命科學公司
    • Organogenesis Inc.
    • BioTissue
    • Skye Biologics Holdings, LLC
    • Tissue Regenix Group
    • Vericel Corporation
    • Stimlabs LLC
    • Tides Medical
    • AlloSource
    • LifeNet Health
    • MTF Biologics
    • 前鋒
    • 康維特
    • Smith+Nephew
Product Code: GVR-3-68038-966-1

Wound Biologics Market Summary

The global wound biologics market size was valued at USD 2.6 billion in 2025 and is projected to grow from USD 2.8 billion in 2026 to USD 4.8 billion in 2033, at a CAGR of 8.1% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 43.5% in 2025. The wound biologics industry's growth is primarily driven by the rising prevalence of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers, coupled with the growing global burden of diabetes and an aging population.

Increasing demand for advanced regenerative therapies, continuous innovations in bioengineered skin substitutes and growth factor-based products, and expanding clinical adoption of biologic wound care solutions to accelerate healing and reduce complications are further supporting market growth.

The increasing prevalence of chronic wounds and diabetes is a major growth driver for the wound biologics market, as diabetic foot ulcers, venous leg ulcers, pressure ulcers, and other non-healing wounds require advanced therapies that promote tissue regeneration and accelerate healing. According to the International Diabetes Federation, diabetes cases continue to rise globally, increasing the number of patients at risk of chronic wound complications. Biologic wound care products, including skin substitutes, placental tissue allografts, and extracellular matrix (ECM)-based therapies, are being adopted to improve healing outcomes, reduce infection risk, and lower amputation rates in patients with complex wounds.

The growing number of surgical procedures and traumatic injuries is a key driver of the wound biologics market, as these conditions often require advanced wound management to accelerate tissue regeneration and reduce the risk of complications, such as infection and delayed healing. Biologic wound care products, including skin substitutes, amniotic membrane allografts, and extracellular matrix (ECM)-based therapies, are increasingly being used in complex surgical wounds, orthopedic procedures, burns, and trauma cases. The rising global surgical volume and increasing incidence of road traffic accidents, sports injuries, and burn injuries continue to expand the demand for regenerative wound biologics across hospitals and trauma centers.

Global Wound Biologics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global wound biologics market report based on product, application, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Biological Skin Substitutes
    • Allograft
    • Xenograft
    • Biosynthetic Products
  • Topical Agents
  • Collagen Dressing
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Chronic Wounds
  • Acute Wounds
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Product
    • 1.1.2. Wound Type
    • 1.1.3. End Use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
  • 1.5. Details of primary research
    • 1.5.1. Data for primary interviews in North America
    • 1.5.2. Data for primary interviews in Europe
    • 1.5.3. Data for primary interviews in Asia Pacific
    • 1.5.4. Data for primary interviews in Latin America
    • 1.5.5. Data for Primary interviews in MEA
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
      • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.2. Volume price analysis (Model 2)
      • 1.7.2.1. Approach 2: Volume price analysis
  • 1.8. Research Scope and Assumptions
    • 1.8.1. List of Secondary Sources
    • 1.8.2. List of Primary Sources
    • 1.8.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Wound Biologics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Rising prevalence of chronic wounds and diabetes
      • 3.2.1.2. Increasing number of surgical procedures and traumatic injuries
      • 3.2.1.3. Rising adoption of regenerative medicine and advanced wound care therapies
      • 3.2.1.4. Growing clinical evidence supporting biologic skin substitutes
      • 3.2.1.5. Increasing incidence of burns and pressure ulcers
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. High cost of biologic wound care products
      • 3.2.2.2. Limited reimbursement coverage across several countries
    • 3.2.3. Market Opportunity Analysis
      • 3.2.3.1. Expansion of regenerative medicine and tissue engineering
      • 3.2.3.2. Development of next-generation bioengineered skin substitutes
      • 3.2.3.3. Growing adoption of placental tissue and extracellular matrix (ECM)-based products
      • 3.2.3.4. Increasing integration of ai and digital wound assessment with biologic therapies
    • 3.2.4. Market Challenge Analysis
      • 3.2.4.1. Stringent regulatory and clinical evidence requirements
      • 3.2.4.2. Pricing pressure and healthcare cost containment measures
  • 3.3. Wound Biologics Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
      • 3.3.2.5. Legal landscape

Chapter 4. Wound Biologics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Wound Biologics Market: Product Movement Analysis, 2025 & 2033 (USD Million)
  • 4.3. Global Wound Biologics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Biological Skin Substitutes
    • 4.4.1. Biological skin substitutes market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Allograft
      • 4.4.2.1. Allograft market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Xenograft
      • 4.4.3.1. Xenograft market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Biosynthetic Products
      • 4.4.4.1. Biosynthetic products market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. Topical Agents
    • 4.5.1. Topical agents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6. Collagen Dressing
    • 4.6.1. Collagen dressing market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Wound Biologics Market: Wound Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Wound Biologics Market: Wound Type Movement Analysis, 2025 & 2033 (USD Million)
  • 5.3. Global Wound Biologics Market Size & Trend Analysis, by Wound Type 2021 to 2033 (USD Million)
  • 5.4. Chronic Wounds
    • 5.4.1. Chronic wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5. Acute Wounds
    • 5.5.1. Acute Wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Wound Biologics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Wound Biologics Market: End use Movement Analysis, 2025 & 2033 (USD Million)
  • 6.3. Global Wound Biologics Market Size & Trend Analysis, by End use 2021 to 2033 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Specialty Clinics
    • 6.5.1. Specialty Clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Ambulatory Surgical Centers
    • 6.6.1. Ambulatory surgical centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Wound Biologics Market: Regional Estimates & Trend Analysis by Product, Wound Type and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size and Trend Analysis, 2021 to 2033
  • 7.3. North America
    • 7.3.1. North America wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. Reimbursement scenario
      • 7.3.2.5. U.S. wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Reimbursement scenario
      • 7.3.3.5. Canada wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Reimbursement scenario
      • 7.3.4.5. Mexico wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Reimbursement scenario
      • 7.4.2.5. UK wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Reimbursement scenario
      • 7.4.3.5. Germany wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Reimbursement scenario
      • 7.4.4.5. France wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Reimbursement scenario
      • 7.4.5.5. Italy wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Reimbursement scenario
      • 7.4.6.5. Spain wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Reimbursement scenario
      • 7.4.7.5. Sweden wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Reimbursement scenario
      • 7.4.8.5. Denmark wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Reimbursement scenario
      • 7.4.9.5. Norway wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Reimbursement scenario
      • 7.5.2.5. China wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Japan
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Reimbursement scenario
      • 7.5.3.5. Japan wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Reimbursement scenario
      • 7.5.4.5. India wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Reimbursement scenario
      • 7.5.5.5. South Korea wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Australia
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Reimbursement scenario
      • 7.5.6.5. Australia wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Reimbursement scenario
      • 7.5.7.5. Thailand wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Reimbursement scenario
      • 7.6.2.5. Brazil wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Reimbursement scenario
      • 7.6.3.5. Argentina wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7. Middle East and Africa
    • 7.7.1. Middle East and Africa wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Reimbursement scenario
      • 7.7.2.5. South Africa wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Reimbursement scenario
      • 7.7.3.5. Saudi Arabia wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. Reimbursement scenario
      • 7.7.4.5. UAE wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Reimbursement scenario
      • 7.7.5.5. Kuwait wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Market Share Analysis, 2025
  • 8.4. Company Heat Map Analysis
  • 8.5. Strategy Mapping
    • 8.5.1. Expansion
    • 8.5.2. Mergers & Acquisition
    • 8.5.3. Partnerships & Collaborations
    • 8.5.4. New Product Launches
    • 8.5.5. Research And Development
    • 8.5.6. Company Profiles
    • 8.5.7. MIMEDX Group, Inc
      • 8.5.7.1. Company overview
      • 8.5.7.2. Financial performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic initiatives
    • 8.5.8. Integra LifeSciences Corporation
      • 8.5.8.1. Company overview
      • 8.5.8.2. Financial performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic initiatives
    • 8.5.9. Organogenesis Inc.
      • 8.5.9.1. Company overview
      • 8.5.9.2. Financial performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic initiatives
    • 8.5.10. BioTissue
      • 8.5.10.1. Company overview
      • 8.5.10.2. Financial performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic initiatives
    • 8.5.11. Skye Biologics Holdings, LLC
      • 8.5.11.1. Company overview
      • 8.5.11.2. Financial performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic initiatives
    • 8.5.12. Tissue Regenix Group
      • 8.5.12.1. Company overview
      • 8.5.12.2. Financial performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic initiatives
    • 8.5.13. Vericel Corporation
      • 8.5.13.1. Company overview
      • 8.5.13.2. Financial performance
      • 8.5.13.3. Product Benchmarking
      • 8.5.13.4. Strategic initiatives
    • 8.5.14. Stimlabs LLC
      • 8.5.14.1. Company overview
      • 8.5.14.2. Financial performance
      • 8.5.14.3. Product Benchmarking
      • 8.5.14.4. Strategic initiatives
    • 8.5.15. Tides Medical
      • 8.5.15.1. Company overview
      • 8.5.15.2. Financial performance
      • 8.5.15.3. Product Benchmarking
      • 8.5.15.4. Strategic initiatives
    • 8.5.16. AlloSource
      • 8.5.16.1. Company overview
      • 8.5.16.2. Financial performance
      • 8.5.16.3. Product Benchmarking
      • 8.5.16.4. Strategic initiatives
    • 8.5.17. LifeNet Health
      • 8.5.17.1. Company overview
      • 8.5.17.2. Financial performance
      • 8.5.17.3. Product Benchmarking
      • 8.5.17.4. Strategic initiatives
    • 8.5.18. MTF Biologics
      • 8.5.18.1. Company overview
      • 8.5.18.2. Financial performance
      • 8.5.18.3. Product Benchmarking
      • 8.5.18.4. Strategic initiatives
    • 8.5.19. Stryker
      • 8.5.19.1. Company overview
      • 8.5.19.2. Financial performance
      • 8.5.19.3. Product Benchmarking
      • 8.5.19.4. Strategic initiatives
    • 8.5.20. Convatec
      • 8.5.20.1. Company overview
      • 8.5.20.2. Financial performance
      • 8.5.20.3. Product Benchmarking
      • 8.5.20.4. Strategic initiatives
    • 8.5.21. Smith+Nephew
      • 8.5.21.1. Company overview
      • 8.5.21.2. Financial performance
      • 8.5.21.3. Product Benchmarking
      • 8.5.21.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America wound biologics market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 4 North America wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 5 North America wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 6 U.S. wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 7 U.S. wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 8 U.S. wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 9 Canada wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 10 Canada wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 11 Canada wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 12 Mexico wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 13 Mexico wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 14 Mexico wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Europe wound biologics market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 17 Europe wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 18 Europe wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Germany wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 20 Germany wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 21 Germany wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 22 UK wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 23 UK wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 24 UK wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 25 France wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 26 France wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 27 France wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 28 Italy wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 29 Italy wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 30 Italy wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 31 Spain wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 32 Spain wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 33 Spain wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Denmark wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 35 Denmark wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 36 Denmark wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Sweden wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 38 Sweden wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 39 Sweden wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 40 Norway wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 41 Norway wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 42 Norway wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific wound biologics market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 47 China wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 48 China wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 49 China wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 50 Japan wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 51 Japan wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 52 Japan wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 53 India wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 54 India wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 55 India wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 56 South Korea wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 57 South Korea wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 58 South Korea wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 59 Australia wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 60 Australia wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 61 Australia wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 62 Thailand wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 63 Thailand wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 64 Thailand wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 65 Latin America wound biologics market, by region, 2021 - 2033 (USD Million)
  • Table 66 Latin America wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 67 Latin America wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 68 Latin America wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 69 Brazil wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 70 Brazil wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 71 Brazil wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 72 Argentina wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 73 Argentina wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 74 Argentina wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 75 MEA wound biologics market, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 77 MEA wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 78 MEA wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 79 South Africa wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 80 South Africa wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 81 South Africa wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 85 UAE wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 86 UAE wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 87 UAE wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 88 Kuwait wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 89 Kuwait wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 90 Kuwait wound biologics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Wound biologics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Data analysis models
  • Fig. 5 Market formulation and validation
  • Fig. 6 Data validating & publishing
  • Fig. 7 Market snapshot
  • Fig. 8 Segment snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Wound biologics - market size and growth prospects (USD million)
  • Fig. 11 Wound biologics market: Industry Value Chain Analysis
  • Fig. 12 Wound biologics market: Market Dynamics
  • Fig. 13 Wound biologics market: PORTER's Analysis
  • Fig. 14 Wound biologics market: PESTEL Analysis
  • Fig. 15 Wound biologics market share by product, 2025 & 2033 (USD Million)
  • Fig. 16 Wound biologics market, by product: market share, 2023 & 2030
  • Fig. 17 Biological skin substitutes market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 18 Allograft market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 19 Xenograft market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 20 Biosynthetic products market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 21 Topical agents market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 22 Collagen dressing market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 23 Wound biologics market share by application, 2025 & 2033 (USD Million)
  • Fig. 24 Wound biologics market, by application: market share, 2025 & 2033
  • Fig. 25 Chronic wounds market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 26 Acute wounds market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 27 Wound biologics market share by end use, 2025 & 2033 (USD Million)
  • Fig. 28 Wound biologics market, by end use: market share, 2023 & 2030
  • Fig. 29 Hospitals market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 30 Specialty clinics market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 31 Ambulatory surgical centers market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 32 Others market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 33 Regional marketplace: key takeaways
  • Fig. 34 North America wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 US wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Canada wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Mexico wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Europe wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 UK wound biologics market estimates and forecasts, 2021 - 2033) (USD Million)
  • Fig. 40 Germany wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 41 France wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 42 Italy wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 43 Spain wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 44 Sweden wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 45 Denmark wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 46 Norway wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 47 Asia Pacific wound biologics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 China wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Japan wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 India wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 South Korea wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Australia wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Thailand wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Latin America wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Brazil wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Argentina wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 MEA wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 South Africa wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Saudi Arabia wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 UAE wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Kuwait wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Key company categorization
  • Fig. 63 Company market positioning
  • Fig. 64 Key company market share analysis, 2025
  • Fig. 65 Strategic framework